NOVAREX CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,460 KRW | -0.73% |
|
+0.21% | -22.08% |
| 21/03 | NOVAREX Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | NOVAREX Co.,Ltd.(KOSDAQ:A194700) dropped from S&P Global BMI Index | CI |
| Sales 2024 * | 330B 240M 20.02B | Sales 2025 * | 360B 261M 21.8B | Capitalization | 170B 124M 10.34B |
|---|---|---|---|---|---|
| Net income 2024 * | 26B 18.9M 1.58B | Net income 2025 * | 28B 20.36M 1.7B | EV / Sales 2024 * | 0.49 x |
| Net cash position 2024 * | 10.15B 7.38M 616M | Net cash position 2025 * | 26.2B 19.05M 1.59B | EV / Sales 2025 * | 0.4 x |
| P/E ratio 2024 * |
6.75
x | P/E ratio 2025 * |
6.24
x | Employees | 405 |
| Yield 2024 * |
1.56% | Yield 2025 * |
1.56% | Free-Float | 57.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.73% | ||
| 1 week | +0.21% | ||
| Current month | -3.96% | ||
| 1 month | -5.87% | ||
| 3 months | -14.00% | ||
| 6 months | -17.02% | ||
| Current year | -22.08% |
1 week
9 390.00
9 790.00
1 month
9 050.0010 290.00
Current year
9 050.0013 230.00
1 year
7 470.0013 880.00
3 years
7 470.0025 350.00
5 years
7 470.0025 350.00
10 years
7 000.0025 350.00
| Managers | Title | Age | Since |
|---|---|---|---|
Suk-Hyung Kwon
CEO | Chief Executive Officer | 69 | 27/08/27 |
Myeong-Jae Han
DFI | Director of Finance/CFO | 65 | - |
Jae-Chul Jung
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Suk-Hyung Kwon
CEO | Chief Executive Officer | 69 | 27/08/27 |
Sang-Jun Lee
CTO | Chief Tech/Sci/R&D Officer | 69 | 01/16/01 |
Bok-Gi Min
PRN | Corporate Officer/Principal | 61 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 9,630 | +1.80% | 41,921 |
| 26/24/26 | 9,460 | -0.73% | 47,469 |
| 25/24/25 | 9,530 | -1.55% | 18,322 |
| 24/24/24 | 9,680 | +1.04% | 31,287 |
| 23/24/23 | 9,580 | -0.10% | 53,465 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
NOVAREX Co.,Ltd. is a Korea-based company principally engaged in the manufacturing and distribution of health functional foods. The Company manufactures and sells nutritional supplement products containing vitamins and minerals; individual recognition products which are helpful for body fat reduction, eye health, and joint health; lactic acid bacteria containing products used for skin condition improvement. The Company also produces and sells coenzyme Q10 products, wild mango seed extract products, spirulina products, as well as others. The Company distributes its products within domestic market to overseas markets.
Sector
Food Processing
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9,630
KRW
Average target price
16,500
KRW
Spread / Average Target
+71.34%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.08% | 122M | |
| +8.20% | 7.78B | |
| +1.64% | 7.38B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.78% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.50% | 879M | |
| -19.38% | 836M |
- Stock Market
- Equities
- A194700 Stock
